Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... release first half and second quarter 2015 financial results ... , 2015.  The Company will host a conference call ... provide a general business update. The conference ... and 1-412-902-4262 (International), and asking to join the "Intrexon ...
(Date:8/3/2015)... According to a new market ... Asia to Witness Highest Growth ... cell culture market was valued at US$ 586.1 Mn in ... of 29.1% to account for US$ 2,717.6 Mn by ... 3D cell culture refers to a ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Corporation (Nasdaq: DNDN ) today announced that management ... in San Francisco on Thursday, January 15, 2009 at 11:00 ... presentation will be accessible through the Investor Relations section of ... to listen to the live webcast, it will be archived ...
... CRANBURY, N.J., Jan. 8 Amicus Therapeutics (Nasdaq: ... J. Barer, Ph.D., to its Board of Directors. ... Officer of Celgene Corporation. As an industry veteran, ... and a reputation as a trusted and respected leader ...
... CAMBRIDGE, Mass. January 7, 2008 Researchers from Harvard ... for the first time, a repulsive quantum mechanical force that ... new nanotechnology applications. , The study, led by Federico Capasso, ... of Engineering and Applied Science (SEAS), will be published as ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Evolution Group participated in an international research that has resulted ... fly species. The study also includes new data on the ... sixty million years. The research, published in Nature, was ... over the world and consisted in the analysis of the ...
... Inc. and the Prostate Cancer Foundation today announced they ... Program (for Special Team Amplification of Research), an innovative ... heat in cancer therapy to treat prostate cancer, as ... is being launched for the first phase of research ...
... (November 15, 2007) -- In response to the need ... populations of the threatened staghorn coral, Diego Lirman, Ph.D., ... Rosenstiel School of Marine and Atmospheric Science (RSMAS) have ... of staghorn corals. The goals of the coral ...
Cached Biology News:Genome comparison of 12 fruit fly species 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4New south Florida nursery to focus on staghorn corals 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: